MAPK10 and COVID-19: Our research suggests that BAD-Indomethacin's inhibition with the other two hub proteins, MAPK8-6MNA, MAPK10-Rofecoxib might play cumulative actions by inactivating the RAS signaling pathway against COVID-19.